NEW YORK (GenomeWeb) – Dutch ag-bio company KeyGene announced today that it has licensed its proprietary sequence-based genotyping technology to LGC and Bayer's Crop Science division.

Under the terms of the separate agreements, KeyGene has given Bayer a non-exclusive license for the in-house use of the SBG technology for crop improvement, and has given LGC a non-exclusive license for the commercial offering and use of SBG technology across all species, including field and vegetable crops, for the global market, the company said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.